Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2023.8585
Abstract: Importance A platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is standard therapy for patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Compared with clopidogrel, prasugrel and ticagrelor are associated with superior… read more here.
Keywords: prasugrel ticagrelor; bleeding risk; therapy; risk ... See more keywords
A Reconciliation Attempt of the Acute Coronary Syndrome Clinical Trials on Clopidogrel, Prasugrel, and Ticagrelor
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-06955-5
Abstract: Dear Editor, Recently, Schüpke and colleagues performed an investigator-initiated head-to-head trial on prasugrel versus ticagrelor in acute coronary syndrome [1]. We highly commend the authors for performing such study. Certainly, given the earlier trials comparing… read more here.
Keywords: ticagrelor; acute coronary; coronary syndrome; prasugrel ticagrelor ... See more keywords
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-021-02386-7
Abstract: Prasugrel and ticagrelor are potent oral platelet P2Y12 inhibitors and are recommended over clopidogrel in patients with acute coronary syndrome (ACS). Oral platelet P2Y12 inhibitors are characterized by varying degrees of pharmacodynamic response profiles as… read more here.
Keywords: use; maintenance dose; ticagrelor; prasugrel ticagrelor ... See more keywords
One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-017-0255-y
Abstract: BackgroundNo direct comparisons of ticagrelor and prasugrel with 1-year clinical follow-up have been reported.ObjectivesOur objective was to compare 1-year clinical outcomes among patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) and… read more here.
Keywords: prasugrel; ticagrelor; study; prasugrel ticagrelor ... See more keywords
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Sign Up to like & getrecommendations! Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2017.02.096
Abstract: BACKGROUND The beneficial use of dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and P2Y12 õinhibitors has been established for patients after acute coronary syndrome (ACS). However, the optimal duration of DAPT is under debate.… read more here.
Keywords: clopidogrel; ticagrelor; patients acute; 2009 2014 ... See more keywords
Seguridad y eficacia clínica con prasugrel y ticagrelor en síndrome coronario agudo. Resultados de un registro multicéntrico en el mundo real
Sign Up to like & getrecommendations! Published in 2017 at "Revista Espanola De Cardiologia"
DOI: 10.1016/j.recesp.2017.02.007
Abstract: Resumen Introduccion y objetivos La incorporacion de los nuevos antiagregantes (NAA) prasugrel y ticagrelor a la practica clinica esta siendo erratica. Los datos del mundo real todavia son escasos. Se analizo la tendencia temporal de… read more here.
Keywords: coronario agudo; con; prasugrel ticagrelor; mundo real ... See more keywords
P3842One-year efficacy and safety of prasugrel and ticagrelor in patients with Acute Coronary Syndromes: results from a prospective and multicenter ACHILLES Registry
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz745.0683
Abstract: Prasugrel and Ticagrelor have demonstrated higher efficacy than clopidogrel in their main clinical trials for patients with Acute Coronary Syndrome (ACS). However, the long-term prognosis and different clinical characteristics related with the type of antiplatelet… read more here.
Keywords: acs; patients acute; year; prasugrel ticagrelor ... See more keywords
Head‐to‐head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta‐analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Interventional Cardiology"
DOI: 10.1111/joic.12416
Abstract: OBJECTIVES We sought to compare the efficacy and safety of prasugrel and ticagrelor in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). BACKGROUND Evidence from randomized head-to-head comparison between prasugrel and ticagrelor is… read more here.
Keywords: head; prasugrel; ticagrelor; prasugrel ticagrelor ... See more keywords
Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study
Sign Up to like & getrecommendations! Published in 2020 at "BMJ Open"
DOI: 10.1136/bmjopen-2020-042229
Abstract: Objectives The objective of this study is to examine the temporal trend of antiplatelet prescribing pattern during index hospitalisation discharge in Hong Kong (HK) acute coronary syndrome (ACS) population. Design The study is a retrospective… read more here.
Keywords: aor; antiplatelet; prasugrel ticagrelor; study ... See more keywords
Clinical outcomes of potent antiplatelets compared with clopidogrel in ST elevation myocardial infarction
Sign Up to like & getrecommendations! Published in 2018 at "Heart"
DOI: 10.1136/heartjnl-2018-312967
Abstract: Real-world clinical studies provide unique insights into how randomised controlled study data are translated into routine clinical practice. Real-world data can highlight areas for improvement and generate new hypotheses. When contemporaneously collected and well characterised, like… read more here.
Keywords: potent antiplatelets; myocardial infarction; prasugrel ticagrelor; elevation myocardial ... See more keywords
Comparative efficacy and safety of oral P2Y12 inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Open Heart"
DOI: 10.1136/openhrt-2021-001937
Abstract: Background Currently, potent P2Y12 inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines recommend the use of… read more here.
Keywords: ticagrelor; prasugrel; oral p2y12; nste acs ... See more keywords